Interprofessional Webinar Series:
Breakthrough Pain: Its Consensus and Controversies
This webinar is presented in collaboration with the
National Hospice and Palliative Care Organization.
Funding Disclosure: No commercial funding has been accepted for the activity.
Date and Time: January 7, 2016, 12:30 PM – 1:30 PM ET (Live)
Location: Online at https://www.mjhspalliativeinstitute.org/e-learning/
Speaker Name and Title:
Russell K. Portenoy, MD
Chief Medical Officer, MJHS Hospice and Palliative Care, New York, NY
Executive Director, MJHS Institute for Innovation in Palliative Care, New York, NY
Professor of Neurology, Albert Einstein College of Medicine, Bronx, NY
Purpose: This webinar will address the concept of breakthrough pain, its evaluation, and the current consensus and controversies regarding its treatment.
Objectives: Participants will be able to:
- Define breakthrough pain and evaluate its characteristics.
- Discuss the various approaches to the treatment of breakthrough pain.
- Understand the benefits and burdens of various opioid therapies used specifically for breakthrough pain.
Why Do I Need to Know This? Breakthrough pain is an episodic transitory pain that “breaks through” an analgesic regimen for chronic pain. It is highly prevalent and is associated with distress, functional impairment, and higher cost of care. A quarter century of research has yielded insights into its characteristics, causes, and optimal treatment, but clinicians often fail to assess and manage it.
Target Audience: palliative care specialists, pain specialists, primary care providers, nurse practitioners, registered nurses, advanced practice nurses, registered nurses with a specialty in palliative care/hospice, pharmacists, allied health professionals, fellows, residents, and medical students
Criteria for Successful Completion:
- Attendance at entire session (mandatory for nurses and pharmacists)
- Submission of completed evaluation form (mandatory to receive CE/CME credit for MDs and nurses)
- Submission of completed Verification of Continuing Education Participation Form, Program Evaluation Form, and CE Validation Form (mandatory for pharmacists). Pharmacists must email all three forms to Shelita Clark at email@example.com or fax forms to 212-649-5544 within 45 days of webinar date.
Continuing Education Credits: 1.0
Continuing Education Accreditation:
Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Hospice and Palliative Care Organization (NHPCO) and MJHS. NHPCO is accredited by the ACCME to provide continuing medical education for physicians.
NHPCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: NHPCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
NHPCO designates this live activity for a maximum of 1.0 contact hour. Nurses should claim only the contact hours commensurate with the extent of their participation in the activity. Accredited status by ANCC refers only to continuing nursing education and does not imply endorsement of any commercial product discussed in conjunction with this activity.
Pharmacists: St. John’s University College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this program provides a total of 1.0 hours of home-study continuing education credit. In order to obtain credit, participants must complete and submit required continuing education forms. The Universal Activity Number assigned to this program is: #0043-9999-15-119-H01-P. Credit will be posted to CPE Monitor within six weeks.
Individual: $25 (includes CME/CE certificate)
Group: $65 + $5 per CME/CE certificate
Registration fees for webinars are not refundable.
Russell K. Portenoy, MD, Faculty and Planner, has indicated a relationship with Pfizer Inc. for research grant support. Any discussion of investigational or unlabeled uses of a product will be identified.
No other Planning Committee Member has any disclosures.
Planning Committee Members
Barbara Bouton, MA, FT
Colleen Fleming-Damon, PhDc, APRN-BC, ACHPN-BC, C.T.
Steven R. Gardner, MPA, PAHM
Myra Glajchen, DSW
Jennifer Kennedy, RN, MA, BSN, CHC
Russell K. Portenoy, MD
Karen Richards, PhD, EdS
Judith A. Skretny